Page 17 - Read Online
P. 17

Page 8 of 11              Schiffmann. Rare Dis Orphan Drugs J 2024;3:4  https://dx.doi.org/10.20517/rdodj.2023.50

               Conflicts of interest
               Raphael  Schiffmann  is  a  consultant  for  Amicus  Therapeutics,  Protalix  Biotherapeutics,  Chiesi
               Pharmaceuticals, and Walking Fish Therapeutics.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.

               Copyright
               © The Author(s) 2024.


               REFERENCES
               1.       Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical fabry disease: a multicenter study. J Am Soc
                   Nephrol 2017;28:1631-41.  DOI  PubMed  PMC
               2.       Desnick RJ, Ioannou YA, Eng CM. α-galactosidase a deficiency: fabry disease. In: The online metabolic and molecular bases of
                   inherited disease. New York: McGraw-Hill Education; 2019.  DOI
               3.       Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it fabry disease? Genet Med 2016;18:1181-5.  DOI  PubMed
               4.       Benjamin ER, Della Valle MC, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated
                   with migalastat. Genet Med 2017;19:430-8.  DOI  PubMed  PMC
               5.       Schiffmann R. Fabry disease. Pharmacol Ther 2009;122:65-77.  DOI  PubMed
               6.       Lenders M, Weidemann F, Kurschat C, et al. Alpha-galactosidase A p.A143T, a non-fabry disease-causing variant. Orphanet J Rare
                   Dis 2016;11:54.  DOI  PubMed  PMC
               7.       Valtola K, Nino-Quintero J, Hedman M, et al. Cardiomyopathy associated with the Ala143Thr variant of the α-galactosidase A gene.
                   Heart 2020;106:609-15.  DOI  PubMed  PMC
               8.       Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in fabry disease:
                   implications for screening studies and ERT. JIMD Rep 2013;8:101-8.  DOI  PubMed  PMC
               9.       Warnock DG. 7th Update on fabry disease: biomarkers, progression and treatment opportunities in 2022. Nephron 2022;146 Suppl
                   1:1-51.  DOI  PubMed
               10.      Valtola K, Hedman M, Kantola I, et al. Late-onset and classic phenotypes of fabry disease in males with the GLA-Thr410Ala mutation.
                   Open Heart 2023;10:e002251.  DOI  PubMed  PMC
               11.      Santostefano M, Cappuccilli M, Gibertoni D, et al. Fabry disease nephropathy: histological changes with nonclassical mutations and
                   genetic variants of unknown significance. Am J Kidney Dis 2023;82:581-596.e0.  DOI
               12.      Johnson B, Mascher H, Mascher D, et al. Analysis of lyso-globotriaosylsphingosine in dried blood spots. Ann Lab Med 2013;33:274-8.
                   DOI  PubMed  PMC
               13.      Viall S, Dennis A, Yang A. Newborn screening for fabry disease in oregon: approaching the iceberg of a143t and variants of uncertain
                   significance. Am J Med Genet C Semin Med Genet 2022;190:206-14.  DOI  PubMed
               14.      Burton BK, Charrow J, Hoganson GE, et al. Newborn screening for lysosomal storage disorders in illinois: the initial 15-month
                   experience. J Pediatr 2017;190:130-5.  DOI
               15.      Macklin S, Laney D, Lisi E, Atherton A, Smith E. The psychosocial impact of carrying a debated variant in the GLA gene. J Genet
                   Couns 2018;27:217-24.  DOI
               16.      Sudhan M, Janakiraman V, Patil R, Oyouni AAA, Hasan Mufti A, Ahmed SSSJ. Asn215Ser, Ala143Thr, and Arg112Cys variants in α
                   -galactosidase A protein confer stability loss in Fabry's disease. J Biomol Struct Dyn 2023;41:9840-9.  DOI  PubMed
               17.      Braun F, Abed A, Sellung D, et al. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest
                   2023;133:e157782.  DOI
               18.      Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule
                   expression in Fabry disease endothelial cells. Mol Genet Metab 2008;95:163-8.  DOI  PubMed  PMC
               19.      Delaleu N, Marti HP, Strauss P, et al. Systems analyses of the fabry kidney transcriptome and its response to enzyme replacement
                   therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. Kidney Int
                   2023;104:803-19.  DOI
               20.      Ryter SW, Lee SJ, Smith A, Choi AM. Autophagy in vascular disease. Proc Am Thorac Soc 2010;7:40-7.  DOI  PubMed  PMC
               21.      Showalter MR, Berg AL, Nagourney A, Heil H, Carraway KL 3rd, Fiehn O. The emerging and diverse roles of bis(monoacylglycero)
                   phosphate lipids in cellular physiology and disease. Int J Mol Sci 2020;21:8067.  DOI  PubMed  PMC
               22.      Hein LK, Duplock S, Fuller M. Selective reduction of bis(monoacylglycero)phosphate ameliorates the storage burden in a THP-1
                   macrophage model of Gaucher disease. J Lipid Res 2013;54:1691-7.  DOI  PubMed  PMC
   12   13   14   15   16   17   18   19   20   21   22